Pilot study shows imaging diagnostic to be well tolerated
CAMBRIDGE, Mass.—Merrimack Pharmaceuticals Inc. has announced Phase 1 results from its clinical pilot study of ferumoxytol, an iron oxide nanoparticle. The study demonstrated that the compound was well tolerated when used as a tumor contrast agent prior to treatment with MM-398, which is being evaluated as a treatment for both metastatic pancreatic cancer and metastatic colorectal cancer.
“This application of ferumoxytol magnetic resonance imaging has the potential to become a minimally invasive predictive biomarker for liposomal therapies. We hope that the continuation and expansion of this approach will allow us to identify patients most likely to benefit from MM-398 treatment … we are encouraged to see that almost all of the tumor lesions that shrank after MM-398 treatment were associated with higher levels of ferumoxytol, as seen on the MRI,” said Dr. Jonathan Fitzgerald, Merrimack’s senior director of discovery.